The emergence of anti-estrogen resistance in breast cancer is an important clinical phenomenon affecting long-term survival in this disease. Identifying factors that convey cell survival in this setting may guide improvements in treatment. Estrogen (E 2 ) can induce apoptosis in breast cancer cells that have been selected for survival after E 2 deprivation for long periods (MCF-7:5C cells), but the mechanisms underlying E 2 -induced stress in this setting have not been elucidated. Here, we report that the c-Src kinase functions as a key adapter protein for the estrogen receptor (ER, ESR1) in its activation of stress responses induced by E 2 in MCF-7:5C cells. E 2 elevated phosphorylation of c-Src, which was blocked by 4-hydroxytamoxifen (4-OHT), suggesting that E 2 activated c-Src through the ER. We found that E 2 activated the sensors of the unfolded protein response (UPR), IRE1a (ERN1) and PERK kinase (EIF2AK3), the latter of which phosphorylates eukaryotic translation initiation factor-2a (eIF2a). E 2 also dramatically increased reactive oxygen species production and upregulated expression of heme oxygenase HO-1 (HMOX1), an indicator of oxidative stress, along with the central energy sensor kinase AMPK (PRKAA2). Pharmacologic or RNA interference-mediated inhibition of c-Src abolished the phosphorylation of eIF2a and AMPK, blocked E 2 -induced ROS production, and inhibited E 2 -induced apoptosis. Together, our results establish that c-Src kinase mediates stresses generated by E 2 in long-term E 2 -deprived cells that trigger apoptosis. This work offers a mechanistic rationale for a new approach in the treatment of endocrine-resistant breast cancer. Cancer Res; 73(14); 1-11. Ó2013 AACR.
Introduction
Developing drugs that target the estrogen receptor (ER) either directly (tamoxifen) or indirectly (aromatase inhibitors) has improved the prognosis of breast cancer (1, 2) . Although aromatase inhibitors show considerable advantages over tamoxifen with respect to patient disease-free survival and tolerability, acquisition of resistance to all forms of endocrine treatments is inevitable (3, 4) . Multiple mechanistic changes are involved in antihormone resistance, which provides the scientific rationale for the clinical development of additional targeted therapies (5, 6) . It is well-known that the biologic actions of E 2 are mediated through the ER, which functions in the nucleus as ligand-dependent transcription factors to promote gene transcription and stimulation of cell growth (7) . Paradoxically, laboratory evidence shows that E 2 can induce apoptosis in sensitive antihormone-resistant cells in vivo (8) (9) (10) . This new targeted strategy provides novel therapeutic approaches to endocrine-resistant breast cancer. A recent phase II clinical trial reports that E 2 provides a clinical benefit for patients with aromatase inhibitor-resistant advanced breast cancer (11) . In addition, the laboratory results on E 2 -induced apoptosis using antihormone-treated MCF-7 cells have been used to explain the reduction of breast cancer and the reduction in mortality observed in postmenopausal hysterectomized women in their 60s treated with conjugated equine estrogen (CEE) when compared with a placebo-treated control (12) . The antitumor action of CEE is observed, not only during CEE treatment but also for 6 years after treatment. These data suggest a cidal effect for CEE and has been noted recently (13) . These encouraging clinical results prompted us to investigate the mechanisms underlying E 2 -induced apoptosis to increase the therapeutic benefits of E 2 in aromatase inhibitor-resistant breast cancer.
Experimental evidence has established the oncogene, c-Src, as a critical component of multiple signaling pathways that regulate proliferation, survival, angiogenesis, and metastasis (14, 15) . Increased c-Src activity is believed to play an important role in the development and progression of breast cancer (16) , and c-Src has been considered as a survival signal for endocrine resistant breast cancer cells (17) . Therefore, a c-Src inhibitor administered as a single-agent or in combination with other antihormone therapy has the potential to enhance the inhibitory effects of antihormones and delay antihormone resistance (18) . These observations highlight c-Src as an important therapeutic target for the treatment of human breast cancer.
Mitochondria are important intracellular organelles involved in apoptosis via an intrinsic pathway (19) . Although the molecular mechanisms of E 2 -induced apoptosis are not fully understood, evidence indicates that mitochondria-related caspase pathways are involved (20, 21) . Similarly, a variety of events in apoptosis focus on mitochondria, including the loss of mitochondrial transmembrane potential, release of cytochrome c, and participation of pro-and antiapoptotic Bcl-2 family proteins (22, 23) . However, accumulating evidence suggests that the endoplasmic reticulum where members of the Bcl-2 family of proteins localize is also a major point of integration of pro-apoptotic signaling or damage sensing (24, 25) . The endoplasmic reticulum senses local stress such as unfolded protein (UPR) through a set of pathways known as the UPR (26) , which activates 3 transmembrane sensors PRKlike endoplasmic reticulum kinase (PERK), inositol-requiring 1 alpha (IRE-1a), and activating transcription factor 6 (ATF-6) in endoplasmic reticulum (26) . Depending on the duration and degree of stress, the UPR can provide either survival signals by activating adaptive and antiapoptotic signals or death signals by inducing cell death programs (27, 28) .
We have found that E 2 changes the cell number according to the treatment period in long-term E 2 -deprived breast cancer cell lines MCF-7:5C and MCF-7:2A (25) . E 2 has the capacity to decrease around 80% of cell number in MCF-7:5C cells after 7 days treatment, whereas in MCF-7:2A cells after 2-week treatment (29) . Unexpectedly, the c-Src inhibitor effectively rescues the decreasing of cell number by E 2 in 2 long-term E 2 -deprived cell lines (29) . The goal of this study is to identify the mechanisms underlying the early stage of E 2 -induced apoptosis and the function of c-Src in the process of E 2 -initiated apoptosis. To that end, we show that E 2 triggers endoplasmic reticulum stress and oxidative stress, which activate 2 main apoptotic pathways, the mitochondrial (intrinsic) and death receptor (extrinsic) pathways, whereas c-Src plays an essential role in mediating stress responses induced by E 2 in MCF-7:5C cells. These findings have important clinical implications for the appropriate application of combination therapies in advanced aromatase inhibitor-resistant breast cancer.
Materials and Methods

Materials
Estradiol was purchased from Sigma-Aldrich. c-Src inhibitor PP2 was purchased from CalBiochem. ERa antibody was from Santa Cruz Biotechnology. Total mitogen-activated protein kinase (MAPK), phosphorylated MAPK, phosphorylated c-Src, phosphorylated eIF2a, total eIF2a, and IRE1a antibodies were from Cell Signaling Technology. Total c-Src mouse antibody was from Millipore. Estrogen dendrimer conjugate (EDC) was a kind gift by Dr. J.A. Katzenellenbogen (University of Illinois at Urbana-Champaign, Urbana, IL).
Cell culture conditions and cell proliferation assays
Estrogen-deprived MCF-7:5C cells were maintained in estrogen-free RPMI-1640 medium supplemented with 10% dextrancoated charcoal-stripped FBS as previously described (20) . The DNA fingerprinting pattern of cell line is consistent with the report by the American Type Culture Collection (29) . The DNA content of the cells, a measure of proliferation, was determined by using a DNA fluorescence quantitation kit (29) .
Cell-cycle analysis
Briefly, MCF-7:5C cells were treated with vehicle (0.1% EtOH) and E 2 (10 À9 mol/L), respectively. Cells were harvested and gradually fixed with 75% EtOH on ice. After staining with propidium iodide (PI), cells were analyzed using a FACSort flow cytometer (Becton Dickinson), and the data were analyzed with ModFit software.
Annexin V analysis of apoptosis
The FITC Annexin V Detection Kit I (BD Pharmingen) was used to quantify apoptosis by flow cytometry according to the manufacturer's instructions. In brief, MCF-7:5C cells were treated with different compounds, respectively. Cells were suspended in 1Â binding buffer and 1 Â 10 5 cells were stained simultaneously with fluorescein isothiocyanate (FITC)-labeled Annexin V (FL1-H) and PI (FL2-H). Cells were analyzed using FACSort flow cytometer (Becton Dickinson).
Mitochondrial/TRANSMEMBRANE potential (Dc m ) detection
Mitochondrial membrane potential was measured by flow cytometry using the cationic lipophilic green fluorochrome rhodamine-123 (Rh123; Molecular Probes) as previously described (20) . Disruption of Dy m is associated with a lack of Rh123 retention and a decrease in fluorescence.
Detection of oxidative stress
Intracellular reactive oxygen species (ROS) were detected by fluorescent dye 2 0 ,7 0 -dichlorofluorescein diacetate (H 2 DCFDA, Invitrogen; ref. 30) . Briefly, MCF-7:5C cells were treated with E 2 for different time points using vehicle (0.1% EtOH) cells as control. Cells were loaded with 1 mmol/L CM-H 2 DCFDA for 10 minutes and washed with PBS twice. Then, cells were monitored at fluorescence 530 nm and an excitation wavelength of 488 nm through flow cytometry.
Immunoblotting
Proteins were extracted in cell lysis buffer (Cell Signaling Technology) supplemented with Protease Inhibitor Cocktail (Roche) and Phosphatase Inhibitor Cocktail Set I and Set II (Calbiochem). The immunoblotting was conducted as previously described (29) .
Transient transfection reporter gene assays
Transient transfection assay was conducted using a dualluciferase system (Promega). To determine ER transcriptional activity, cells were transfected with an estrogen response element (ERE)-regulated (pERE (5Â) TA-ffLuc plus pTA-srLuc) dual-luciferase reporter gene sets. The cells were treated with E 2 for 24 hours following the transfection. Then, the cells were harvested and processed for dual-luciferase reporter activity, in which the firefly luciferase activity was normalized by Renilla luciferase activity.
Quantitative real-time reverse transcription PCR Total RNA, isolated with an RNeasy Micro Kit (Qiagen), was converted to first-strand cDNA using a kit from Applied Biosystems. Quantitative real-time PCR assays were done with the SYBR Green PCR Master Mixes (Applied Biosystems) and a 7900HT Fast Real-time PCR System (Applied Biosystems). All primers were synthesized in Integrated DNA Technologies. The sequence of primers is shown in the Supplementary Table S1. All the data were normalized by 36B4.
RNA sequencing analysis
MCF-7:5C cells were treated with different compounds for 72 hours. Cells were harvested in TRIzol. Total RNA was isolated with an RNeasy Micro Kit. These long RNA samples were first converted into a library of cDNA fragments. Sequencing adaptors were subsequently added to each cDNA fragment and a 2 Â 100 bp paired-end sequence was obtained from each cDNA using high-throughput sequencing technology (Illumina GAII). An average of 73.8 million such reads was produced for each sample. The resulting sequence reads were aligned to reference genome build hg19 using TopHat 1.3.0 (31), a splice junction aligner. Transcript abundance was estimated as Fragments Per Kilobase of exon per Million fragments mapped (FPKM), using Cufflinks 1.0.3 (32) . Additional analysis was conducted with the alternative expression analysis by sequencing (Alexa-seq) software package as previously described (33) . Gene expression measures were compared between Cufflinks and Alexa-seq for the set of 17,993 overlapping genes. Correlations were excellent with Spearman correlations of 0.955 to 0.971 for the 6 samples. Pathway analysis was conducted with DAVID (34) on lists of differentially expressed gene lists.
Statistical analysis
All reported values are the means AE SE. Statistical comparisons were determined with 2-tailed Student t tests. Results were considered statistically significant if the P < 0.05.
Results
c-Src mediated estrogen-activated growth pathways in long-term estrogen-deprived breast cancer cells MCF-7:5C
It is well-documented that E 2 stimulates growth and prevents apoptosis in wild-type breast cancer cells and estrogenresponsive osteoblast cells (35, 36) . In contrast, physiologic concentrations of E 2 induce apoptosis in long-term E 2 -deprived breast cancer cells (20, 21) . c-Src plays a critical role in relaying ER signaling pathways in breast cancer cells (37) . To investigate the function of E 2 and c-Src in long-term E 2 -deprived breast cancer cells MCF-7:5C, a specific c-Src tyrosine kinase inhibitor, PP2, was used to block phosphorylation of c-Src (Fig. 1A) . It also effectively abolished the growth pathways including the MAPK and phosphoinositide 3-kinase (PI3K)/AKT pathways in MCF-7:5C cells (Fig. 1A ). E 2 activated c-Src through ER as 4-hydroxytamoxifen (4-OHT) completely suppressed phosphorylation of c-Src (Fig. 1B) . Although our previous finding showed that E 2 initiates apoptosis in MCF-7:5C cells (20), E 2 was able to activate nongenomic (Supplementary Fig. S1A ) and genomic pathways in MCF-7:5C cells (Fig. 1C) . These actions were blocked by the c-Src inhibitor, PP2 ( Fig. 1C and Supplementary Fig. S1A ). Even though the characteristic E 2 -induced apoptosis occurs after 72-hour treatment (20) , cell numbers were initially increased by E 2 with a high percentage in S-phase (Fig. 1D ). All of these results suggested that E 2 caused an imbalance between growth and apoptosis in MCF-7:5C cells.
Inhibition of c-Src suppressed estrogen-induced apoptosis in MCF-7:5C cells
We have shown that long-term E 2 deprivation increases cSrc activity (29) . Therefore, we addressed the question of whether the c-Src inhibitor, PP2, in combination with E 2 would enhance apoptosis in MCF-7:5C cells. Unexpectedly, the c-Src inhibitor blocked apoptosis initiated by E 2 ( Fig. 2A and Supplementary Fig. S1D ). To confirm that inhibition of c-Src could block E 2 -induced apoptosis, a specific siRNA was used to knock down c-Src in MCF-7:5C cells (Fig. 2B) , which reduced the percentage of Annexin V binding induced by E 2 (Fig. 2C) . Further experiments showed that E 2 disrupted mitochondrial membrane potential (Dy m ) after 48-hour treatment, which was measured by flow cytometry using Rh123 (Fig. 2D) . The c-Src inhibitor PP2 and 4-OHT both prevented reduction of Rh123 retention induced by E 2 (Fig. 2D ). These data showed that E 2 -triggered apoptosis use the c-Src tyrosine kinase pathway. To evaluate the role of the nongenomic pathway in E 2 -induced apoptosis, studies were completed with a synthetic ligand, EDC, that only activates the nongenomic pathway at certain concentration (38) . The results showed that EDC (10 À8 mol/L) activated the nongenomic pathway incorporating c-Src ( Supplementary Fig. S2 ). Importantly, EDC had no capacity to activate endogenous E 2 target gene pS2 and did not induce apoptosis in MCF-7:5C cells ( Supplementary Fig. S2 ). All of these findings suggested that the nongenomic pathway does not play a critical role in triggering E 2 -induced apoptosis.
Suppression of E 2 -induced apoptosis by the c-Src inhibitor was independent of the classical ERE-regulated transcriptional genes in MCF-7:5C cells
The ER is the initial site for E 2 to induce apoptosis as antiestrogens ICI 182,780 and 4-OHT completely block apoptosis triggered by E 2 (ref. 20 and Supplementary Fig. S3A ). In addition to the mediation of ER growth pathways, c-Src is involved in the process of ligand-activated ER ubiquitylation (39) . Therefore, blockade of c-Src tyrosine kinase with PP2 further increased ERa protein and mRNA expression levels in MCF-7:5C cells (Fig. 3A) . E 2 activated ERE activity, which could be blocked by 4-OHT but not by PP2 (Fig. 3B) . It was interesting to find that the c-Src inhibitor alone could upregulate E 2 -inducible gene pS2 and was additive with E 2 to elevate pS2 mRNA level (Fig. 3C) . Another important ER target gene progesterone receptor (PR) has been regarded as an indicator of a functional ER pathway, as expression of PR is regulated by E 2 . Although the c-Src inhibitor alone did not elevate PR expression, it dramatically synergized with E 2 to upregulate PR mRNA (Fig. 3D) . All of these results showed that blockade of c-Src increased expression of classical ER target genes. It also implied that classical ER pathway might not directly involve in the E 2 -induced apoptosis.
c-Src was involved in the process of triggering apoptosisrelated genes by E 2 in MCF-7:5C cells
To further investigate the mechanisms of the suppression of E 2 -induced apoptosis by PP2, RNA-seq analysis was conducted to examine the genes regulated by E 2 to trigger apoptosis in MCF-7:5C cells. A wide range of apoptosis-related genes was activated by E 2 (Fig. 4A ), which were functionally classified into 3 groups: TP53-related genes (such as TP63, PMAIP1, and CYFIP2), stress-related genes (such as HMOX1, PPP1R15A, ZAK, NUAK2, etc.), and inflammatory response-related genes (such as LTB, FAS, TNFRSF21, CXCR4, etc.). Most were stress-related genes ( Supplementary Fig. S3B ). Consistent with the biologic experiments, 4-OHT and PP2 both blocked apoptosis-related genes induced by E 2 but to a different extent in MCF-7:5C cells (Fig. 4A) . The majority of these apoptosis-related genes were confirmed by real-time PCR with similar changes noted as in RNA-seq analysis (Fig. 4B-D and Supplementary Fig. S4 ). E 2 dramatically increased p63 mRNA levels (Fig. 4B ) but did not arrest cells in the G 1 phase. In fact, S-phase was markedly elevated in MCF-7:5C cells (Fig. 1D) . Heme oxygenase 1 (HMOX1), which is active at high concentrations of heme, catalyzes the degradation of heme and is thought to function as an oxidative stress indicator (40) . In breast cancer cells, cytochrome c is a major source of heme protein found in the inner membrane of the mitochondrion. E 2 markedly increased HMOX1 in MCF-7:5C cells (Fig. 4C) , thereby confirming that E 2 may damage the mitochondria and caused cytochrome c release. In contrast to MCF-7:5C cells, E 2 decreased HMOX1 levels in wild-type MCF-7 cells (Supplementary Fig. S5A ) and clearly did not change HMOX1 expression in another long-term E 2 -deprived cell line MCF-7:2A ( Supplementary Fig. S5B ), both of MCF-7 and MCF-7:2A do not undergo apoptosis after exposure to E 2 in the first 3 days. In addition, E 2 upregulated TNF family members (such as TNFa, LTA, and LTB), which were abolished by 4-OHT and PP2 (Fig. 4D and Supplementary  Fig. S6A and S6B ). Low dose of TNFa activated pro-apoptotic pathways in MCF-7:5C cells and inhibited cell growth (Supplementary Fig. S6C and S6D ). All of these data suggested that E 2 widely activated intrinsic and extrinsic apoptosis pathways and c-Src was directly involved in mediating apoptosis.
The c-Src inhibitor blocked estrogen-induced oxidative stress in MCF-7:5C cells
ROSs are the product of oxidative stress by mitochondria, whereas an increase in ROS contributes to degenerative changes in mitochondrial function (41 low-molecular-weight radical scavengers and by a complex intracellular network of enzymes such as catalases (CAT) and superoxide dismutases (SOD). Under conditions of lethal stress, ROSs are considered as key effectors of cell death (42) . Intracellular ROSs were detected by CM-H 2 DCFDA through flow cytometry (Fig. 5A) . Detectable ROS appeared after 48 hours of treatment with E 2 . The production of ROS reached a peak after 72-hour treatment ( Fig. 5A and B ). Blocking ER (by 4-OHT) and c-Src (by PP2) abolished ROS generation induced by E 2 (Fig. 5C ), indicating that both ER and c-Src were upstream signals of ROS. Free-radical scavengers Mn-TBAP, catalase, and sodium formate (SF) that respectively act on superoxide radical (O 2 À ), H 2 O 2 , and hydroxyl radical (OH À ) were used to suppress the production of ROS. Our results suggested that H 2 O 2 and OH À were the major sources of ROS induced by E 2 . This conclusion was based on the observation that catalase and sodium formate inhibited E 2 -induced apoptosis, whereas Mn-TBAP was less effective (Fig.  5D ). The RNA-seq analysis showed that E 2 did not significantly regulate antioxidant enzymes such as catalases (CAT) and superoxide dismutases (SOD) in MCF-7:5C cells (data not shown). Our results suggest that E 2 has the potential to damage mitochondria to cause oxidative stress.
c-Src was involved in estrogen-induced endoplasmic reticulum stress in MCF-7:5C cells Our previous global gene array data show that E 2 activates genes related to endoplasmic reticulum stress in MCF-7:5C cells (25) . To relieve stress, sensors of UPRs are activated as initial responses (43) . In this study, a significant induction of UPR sensors, inositol-requiring protein 1 alpha (IRE1a) and PERK/eukaryotic translation initiation factor-2a 
PP2 Con
Relative ER α levels detected by immunoblotting. ERa mRNA was quantified with quantitative PCR (qPCR). Ã , P < 0.05, compared with control. B, MCF-7:5C cells were transfected with ERE firefly luciferase plasmid plus Renilla luciferase plasmid. Then, cells were treated with different compounds respectively for 24 hours to detect ERE activity. ÃÃ , P < 0.001, compared with control. C, MCF-7:5C cells were treated with different compounds respectively for 24 hours. The pS2 mRNA was quantified with qPCR. ÃÃ , P < 0.001, compared with control. D, MCF-7:5C cells were treated with different compounds respectively for 72 hours. The PR mRNA was quantified with qPCR. ÃÃ , P < 0.001, compared with control.
occurred after 24 hours of treatment and was further increased by prolonging treatment times in MCF-7:5C cells (Fig. 6A) . The anti-estrogen 4-OHT completely abolished the response (Fig.  6A) . The PERK inhibitor blocked phosphorylation of eIF2a and prevented E 2 -induced apoptosis ( Fig. 6B and C) , confirming that endoplasmic reticulum stress was important in the apoptosis initiated by E 2 . Phosphorylated eIF2a closely associates with an important cellular energy sensor, adenosine monophosphate (AMP)-activated protein kinase (AMPK) to regulate protein translation and apoptosis (44) . AMPK, which phosphorylates many metabolic enzymes to stimulate catabolic pathways and increases the capacity of cells to produce ATP (45) , was significantly activated after 48-hour treatment with E 2 (Fig. 6D) . The c-Src inhibitor, PP2, blocked the phosphorylation of eIF2a but not IRE1a induced by E 2 (Fig.  6E ). PP2 also prevented the activation of AMPK after E 2 treatment (Fig. 6F) . All of these data indicate that c-Src acts as an important transducer in the protein kinase pathways (eIF2a and AMPK) of stress response ( Fig. 6E and F) that result in apoptosis.
Discussion
We have previously investigated the inhibitory effects of E 2 on long-term endocrine-resistant breast cancer tumor growth in vivo (8-10). And we have confirmed that this therapeutic effect is related with the apoptosis induced by E 2 (20) . This scientific discovery has been used in the clinical trials to treat aromatase inhibitor-resistant patients with breast cancer and 30% of patients receive benefit (11) . The potential limitation on translational research in the treatment of hormone-responsive breast cancer is that only 4 ER-positive breast cancer cell lines are available to use routinely (46) . Only MCF-7 of the 4 produces the phenotype of E 2 -induced apoptosis observed clinically (20, 21) . The purpose of establishing long-term E 2 deprivation in vitro models is to mimic administration of an aromatase inhibitor that reduces levels of circulating estrogen in clinical studies (47) . After a period of proliferative quiescence lasting a few months, the return of proliferation is similar to the relapses observed 12 to 18 months after primary hormonal therapy in patients. Multiple pathways are involved in the adaptive response to the pressure of E 2 deprivation (48). Although MCF-7 cells grown long-term have been shown to differ substantially in various properties depending upon the number of passages and geographic source of the cell lines, induction of apoptosis by physiologic concentrations of E 2 is the common characteristic of these in vitro model systems (20, 21) . Nevertheless, how E 2 induces apoptosis is at present unclear. Our new observation (29) that a c-Src inhibitor paradoxically can block E 2 -induced apoptosis naturally demands further study. We examined this aspect of c-Src pharmacology to describe fully this phenomenon and gain an insight into the convergence of ER and c-Src pathways for the modulations of an apoptotic trigger in breast cancer. Here, for the first time, we document that c-Src participates in the mediation of stress responses induced by E 2 to widely activate apoptosis-related genes involved in the intrinsic and the extrinsic apoptosis pathways.
The ER is the initial point for E 2 to induce apoptosis, as antiestrogens ICI 182,780 and 4-OHT completely block apoptosis triggered by E 2 (ref. 20 and Supplementary Fig. S3A ). Contradictory to the traditional apoptosis mechanism caused by cytotoxic chemotherapy with cell-cycle arrest, E 2 -induced apoptotic cells simultaneously undergo proliferation with an increased S-phase of cell cycle resulting in increased cell number despite p53 family members being upregulated (Figs.  1D and 4B ). E 2 exerts a dual function on MCF-7:5C cells, with both initial proliferation and the apoptosis. In other words, the initial response of E 2 to stimulate growth is the upregulating of classical transcriptional activity by ER (Fig. 3B) without any detected apoptotic changes in the first 24 hours. Activation of apoptotic genes appeared after 48-hour treatment with E 2 (data not shown) and reached a peak by 72 hours (Fig. 4B-D) . Consistently, characteristic apoptosis occurred at 72 hours ( Fig. 2A) . These data suggest that the higher rate of proliferation by E 2 might activate other pathways to trigger apoptosis. Our data show that E 2 caused endoplasmic reticulum stress, which activated the UPR within 24 hours (Fig. 6A) . The initial aim of UPR is to restore normal function of the cell; however, if the damage is too severe to repair, the UPR ultimately initiates cell death through activation of the apoptotic pathway (49) . c-Src functioned as an important downstream signal of ER in MCF-7:5C cells, which was activated by E 2 (Fig. 1B , Supplementary Fig. S1A-S1C ) and showed multiple levels of association with ER (Figs. 1B and C, 2A, 3A, C, and D ). An important finding in this study is that c-Src tyrosine kinase is critical for E 2 -induced apoptosis ( Fig. 2A, C, and D) . This, therefore, raised the question of the actual role played by c-Src in the process of apoptosis induced by E 2 . c-Src mediated PI3K/AKT and MAPK growth pathways by E 2 (Fig. 1C) . However, specific inhibitors of PI3K/Akt (LY294002) and MAPK (U0126) could inhibit cell growth but did not prevent E 2 -induced apoptosis in MCF-7:5C cells ( Supplementary Fig. S7 ), which imply that MAPK/Akt growth pathways are not directly involved in the apoptosisinduced by E 2 . In MCF-7:5C cells, E 2 activated the nongenomic pathway after 10-minute treatment and the c-Src inhibitor blocked the nongenomic pathway ( Supplementary Fig. S1A and S1B). Detectable elevation of c-Src phosphorylation appeared after 30-minute treatment with E 2 ( Supplementary  Fig. S1B ). Consistent stimulation of c-Src appeared after 24-hour treatment and gradually increased when extending to 48 hours (Fig. 1B and Supplementary Fig. S1C ). All of these data suggest that c-Src activation is a direct effect resulting from E 2 .
To further explore the function of the nongenomic pathway in the process of E 2 -induced apoptosis, EDC was used to treat MCF-7:5C cell, which is very ineffective in stimulating transcription of endogenous E 2 target genes (38) . The EDC (10 À8 mol/L) activated the nongenomic pathway but without capacity to activate genomic pathway and did not induce apoptosis in MCF-7:5C cells ( Supplementary Fig. S2 ). All of these results suggest that the nongenomic pathway does not play a critical role in the E 2 -induced apoptosis. Interestingly, the EDC could continuously activate c-Src and Akt but without mol/L), respectively, for 24 hours. Phosphorylated eIF2a was examined as the downstream of PERK. Total eIF2a was determined for loading control. C, MCF-7:5C cells were treated with E 2 or combined with PERK inhibitor, respectively, for 72 hours. Apoptosis was detected through Annexin V binding assay. D, MCF-7:5C cells were treated with E 2 or combined with 4-OHT as above. Phosphorylated AMPK was examined by immunoblotting. Total AMPK was determined for loading control. E, MCF-7:5C cells were treated with E 2 or combined with PP2 for 24 hours. IRE1a and phosphorylated eIF2a were examined by immunoblotting. Total eIF2a and b-actin were determined for loading controls. F, MCF-7:5C cells were treated with E 2 or combined with PP2 for 48 hours. Phosphorylated AMPK and total AMPK were examined by immunoblotting.
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any effect on MAPK after 24-hour treatment ( Supplementary  Fig. S2E ), which may be resulted from enhanced association between ERa and membrane growth factor receptor (48) . In addition, E 2 activated classical ERE activity but the c-Src inhibitor could not block the response (Fig. 3B) . Furthermore, the c-Src inhibitor collaborated with E 2 to upregulate endogenous ER target genes pS2 and PR (Fig. 3C and D) . All of these results imply that classical ER transcriptional pathways are not directly involved in E 2 -induced apoptosis. Similarly, Zhang and colleagues reported that the inhibitory effects of E 2 on cell growth are independent of the classical ERE-regulated transcriptional genes (50) . Our global gene array data suggest that E 2 signaling can occur through a nonclassical transcriptional pathway involving the interaction of ER with other transcription factors such as activator protein-1 (AP-1) and Sp1, which may regulate stress responses (25) . In the present study, E 2 initiated UPR (Fig. 6A) , increased ROS production (Fig. 5A) , and widely activated apoptosis-related genes (Fig. 4A) . The c-Src was involved in the stress responses and inhibition of c-Src decreased the expression of apoptosis-related genes induced by E 2 , which are critical mechanisms for the blockade of c-Src to prevent E 2 -induced apoptosis.
Overall, E 2 induces endoplasmic reticulum and mitochondrial stresses in MCF-7:5C cells, which subsequently upregulates apoptosis-related genes to activate intrinsic and extrinsic apoptotic pathways. Unexpectedly, c-Src tyrosine kinase plays a critical role in the stress response induced by E 2 . These data clearly raise a concern about the ubiquitous use of c-Src inhibitors to treat patients with advanced aromatase inhibitor-resistant breast cancer, thereby undermining the beneficial effects of E 2 -induced apoptosis.
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